Purpose: To detect early diabetic damage in type 2 diabetes mellitus patients with no diabetic retinopathy (NDR) using optical coherence tomography (OCT) and to evaluate OCT as a clinical test. Methods: Thirty-two patients with NDR (n = 32) were enrolled. We examined retinal and retinal nerve fiber layer (RNFL) thickness using OCT. Two healthy normal populations were also enrolled for the retinal thickness (n = 48) and RNFL thickness (n = 34). Both OCT measurements were obtained in four areas (temporal, superior, nasal and inferior). The receiver operator characteristic (ROC) curve was generated to evaluate the predictor variables. Results: Comparing the normal and NDR eyes, retinal thickness significantly increased (p = 0.03) and RNFL thickness significantly decreased (p = 0.02) in the superior areas. The area under the ROC curve was 0.65 for the superior retinal thickness and 0.63 for the superior RNFL thickness. Conclusions: Both OCT measurements can detect early retinal damage in NDR patients.

Keywords:
Optical coherence tomography, Retinal nerve fiber layer thickness, Retinal thickness
1.
Kroll P, Wiegand W: Vitrectomy for tractional optic nerve pseudoatrophy in diabetic vitreoretinopathy. Ophthalmology 1995;102(suppl):95.
2.
Ghirlanda G, Di Leo MA, Caputo S, Falsini B, Porciatti V, Marietti G, Greco AV: Detection of inner retina dysfunction by steady-state focal electroretinogram pattern and flicker in early IDDM. Diabetes 1991;40:1122–1127.
3.
Nomura R, Terasaki H, Hirose H, Miyake Y: Blue-on-yellow perimetry to evaluate S cone sensitivity in diabetes. Ophthalmic Res 2000;32:69–72.
4.
Remky A, Arend O, Hendricks S: Short-wavelength automated perimetry and capillary density in early diabetic maculopathy. Invest Ophthalmol Vis Sci 2000;41:274–281.
5.
Weinreb RN, Zangwill L, Berry CC, Bathija R, Sample PA: Detection of glaucoma with scanning laser polarimetry. Arch Ophthalmol 1998;116:1583–1589.
6.
Zeimer R, Shahidi M, Mori M, Zou S, Asrani S: A new method for rapid mapping of the retinal thickness at the posterior pole. Invest Ophthalmol Vis Sci 1996;37:1994–2001.
7.
Hee MR, Izatt JA, Swanson EA, Huang D, Schuman JS, Lin CP, Puliafito CA, Fujimoto JG: Optical coherence tomography of the human retina. Arch Ophthalmol 1995;113:325–332.
8.
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flote T, Gregory K, Puliafito CA: Optical coherence tomography. Science 1991;254:1178–1181.
9.
Fujimoto JG, Brezinski ME, Tearney GJ, Boppart SA, Bouma B, Hee MR, Southern JF, Swanson EA: Optical biopsy and imaging using optical coherence tomography. Nat Med 1995;1:970–972.
10.
Muscat S, Parks S, Kemp E, Keating D: Repeatability and reproducibility of macular thickness measurements with the Humphrey OCT system. Invest Ophthalmol Vis Sci 2002;43:490–495.
11.
Villain MA, Greenfield S: Peripapillary nerve fiber layer thickness measurement reproducibility using optical coherence tomography. Ophthalmic Surg Lasers Imaging 2003;34:33–37.
12.
Alamouti B, Funk J: Retinal thickness decreases with age: an OCT study. Br J Ophthalmol 2003;87:899–901.
13.
Yasukawa T, Kiryu J, Tsujikawa A, Dong J, Suzuma I, Takagi H, Ogura Y: Quantitative analysis of foveal retinal thickness in diabetic retinopathy with the scanning retinal thickness analyzer. Retina 1998;18:150–155.
14.
Weinberger D, Axer-Siegel R, Landau D, Yassur Y: Retinal thickness variation in the diabetic patient measured by the retinal thickness analyser. Br J Ophthalmol 1998;82:1003–1006.
15.
Oshima Y, Emi K, Yamanishi S, Motokura M: Quantitative assessment of macular thickness in normal subjects and patients with diabetic retinopathy by scanning retinal thickness analyser. Br J Ophthalmol 1999;83:54–61.
16.
Fritsche P, van der Heijde R, Suttorp-Schulten MS, Polak BC: Retinal thickness analysis (RTA): an objective method to assess and quantify the retinal thickness in healthy controls and in diabetics without diabetic retinopathy. Retina 2002;22:768–771.
17.
Goebel W, Kretzchmar-Gross T: Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina 2002;22:759–767.
18.
Pires I, Bernardes RC, Lobo CL, Soares MA, Cunha-Vaz JG: Retinal thickness in eyes with mild nonproliferative retinopathy in patients with type 2 diabetes mellitus: comparison of measurements obtained by retinal thickness analysis and optical coherence tomography. Arch Ophthalmol 2002;120:1301–1306.
19.
Schaudig UH, Glaefke C, Scholz F, Richard G: Optical coherence tomography for retinal thickness measurement in diabetic patients without clinically significant macular edema. Ophthalmic Surg Lasers 2000;31:182–186.
20.
Pires I, Bernardes RC, Lobo CL, Soares MA, Cunha-Vaz JG: Retinal thickness in eyes with mild nonproliferative retinopathy in patients with type 2 diabetes mellitus: comparison of measurements obtained by retinal thickness analysis and optical coherence tomography. Arch Ophthalmol 2002;120:1301–1306.
21.
Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–1806.
22.
Schuman JS, Hee MR, Puliafito CA, Wong C, Pedut-Kloizman T, Lin CP, Hertzmark E, Izatt JA, Swanson EA, Fujimoto JG: Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol 1995;113:586–596.
23.
Wakitani Y, Sasoh M, Sugimoto M, Ito Y, Uji Y: Macular thickness measurements in healthy subjects with different axial length using optical coherence tomography. Retina 2003;23:177–182.
24.
Schuman JS, Pedut-Kloizman T, Hertzmark E, Hee MR, Wilkins JR, Coker JG, Puliafito CA, Fujimoto JG, Swanson EA: Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography. Ophthalmology 1996;103:1889–1898.
25.
Hoyt WF, Schlicke B, Eckelhoff RJ: Fundoscopic appearance of a nerve-fibre-bundle defect. Br J Ophthalmol 1972;56:577–583.
26.
Chihara E, Matsuoka T, Ogura Y, Matsumura M: Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology 1993;100:1147–1151.
27.
Bartz-Schmidt KU, Schmitz-Valckenberg P: Retinal nerve fiber layer photography and papillometry in juvenile diabetes mellitus. Ophthalmologe 1994;91:364–367.
28.
Bowd C, Weinreb RN, Williams JM, Zangwill LM: The retinal nerve fiber layer thickness in ocular hypertensive, normal, and glaucomatous eyes with optical coherence tomography. Arch Ophthalmol 2000;118:22–26.
29.
Chauhan DS, Marshall J: The interpretation of optical coherence tomography images of the retina. Invest Ophthalmol Vis Sci 1999;40:2332–2342.
30.
Lopes de Faria JM, Russ H, Costa VP: Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol 2002;86:725–728.
31.
Ozdek S, Lonneville YH, Onol M, Yetkin I, Hasanreisoglu BB: Assessment of nerve fiber layer in diabetic patients with scanning laser polarimetry. Eye 2002;16:761–765.
32.
Weinreb RN: Evaluating the retinal nerve fiber layer in glaucoma with scanning laser polarimetry. Arch Ophthalmol 1999;117:1403–1406.
33.
Greenfield DS, Knighton RW, Feuer WJ, Schiffman JC, Zangwill L, Weinreb RN: Correction of corneal polarization axis improves the discriminating power of scanning laser polarimetry. Am J Ophthalmol 2002;134:27–33.
34.
Zangwill LM, Bowd C, Berry CC, Williams J, Blumenthal EZ, Sanchez-Galeana CA, Vasile C, Weinreb RN: Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph. Arch Ophthalmol 2001;119:985–993.
35.
Bowd C, Zangwill LM, Berry CC, Blumenthal EZ, Vasile C, Sanchez-Galeana C, Bosworth CF, Sample PA, Weinreb RN: Detecting early glaucomatous by assessment of retinal nerve fiber layer thickness and visual function. Invest Ophthalmol Vis Sci 2001;42:1993–2003.
36.
Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montanes J, Garcia-Layana A: Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588–1594.
37.
Weinreb RN, Shakiba S, Zangwill L: Scanning laser polarimetry to measure the nerve fiber layer of normal and glaucomatous eyes. Am J Ophthalmol 1995;119:627–636.
38.
Weinreb RN, Shakiba S, Sample PA, Sharokni S, van Horn S, Garden VS, Asawaphureekorn S, Zangwill L: Association between quantitative nerve fiber layer measurement and visual field loss in glaucoma. Am J Ophthalmol 1995;120:732–738.
39.
Caprioli J: The contour of the juxtapapillary nerve fiber layer in glaucoma. Ophthalmology 1990;97:358–366.
40.
Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR: Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. Am J Ophthalmol 1983;95:673–691.
41.
Kern TS, Engerman RL: Vascular lesions in diabetes are distributed non-uniformly within the retina. Exp Eye Res 1995;60:545–549.
42.
Chihara E: Impairment of protein synthesis in the retinal tissue in diabetic rabbits: secondary reduction of fast axonal transport. J Neurochem 1981;37:247–250.
43.
Chihara E, Sakugawa M, Entani S: Reduced protein synthesis in diabetic retina and secondary reduction of slow axonal transport. Brain Res 1982;250:363–366.
44.
Dick JSB: Macular edema; in Dunn JP (ed): International Ophthalmology Clinics. Macular Diseases. Philadelphia, Lippincott Williams & Wilkins, 1999, volume 4, pp 1–18.
45.
Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy. Early Treatment Diabetic Retinopathy Study report number 12. Ophthalmology 1991;98:823–833.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.